SERA Share Price Performance
US$1.88
-0.34 (-15.32%)
62.4% undervalued intrinsic discount
US$5.00
Fair Value
Price US$1.88
AnalystConsensusTarget US$5.00
Fair ValueUS$5.00
Share Pricen/a
Sera Prognostics, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
SERA Community Narratives
AN
Fair Value
·Fair Value US$5 61.6% undervalued intrinsic discount
Medicaid Expansion And Maternal Health Focus Will Drive Long-Term Opportunity In Preterm Birth Prevention
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Medicaid Expansion And Maternal Health Focus Will Drive Long-Term Opportunity In Preterm Birth Prevention
Catalysts About Sera Prognostics Sera Prognostics develops and commercializes biomarker based blood tests to predict risk of preterm birth and enable targeted, cost effective prenatal care. What are the underlying business or industry changes driving this perspective?Read more
AN
US$5
61.6% undervalued intrinsic discount
Fair Value
Profit Margin
16.03%
Future PE
138.16x
Price in 2028
US$6.14
Trending Discussion
Recently Updated Narratives
AN
Medicaid Expansion And Maternal Health Focus Will Drive Long-Term Opportunity In Preterm Birth Prevention
Fair Value: US$5 61.6% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Sera Prognostics, Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- -0.82
- -191.23%
- -56,385.96%
- 0%
About SERA
- Founded
- 2008
- Employees
- 72
- CEO
- WebsiteView website
Sera Prognostics, Inc., a women’s health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
